{"entity":{"id":"yl211","kind":"drug","name":"YL211","aka":[],"tldr":"YL211 is an experimental antibody-drug conjugate aimed at c-MET, a protein on some solid tumours. MediLink Therapeutics licensed worldwide rights to Roche in January 2024, and it is in a first phase 1 trial.","summary":"YL211 is an antibody-drug conjugate that targets c-MET (mesenchymal-epithelial transition factor) and uses MediLink Therapeutics' TMALIN conjugate platform. MediLink and Roche announced a worldwide collaboration and licence on 2 January 2024, with USD 50 million in upfront and near-term payments and a total deal value nearing USD 1 billion; MediLink was to run the first phase 1 trial with Roche's China Innovation Center before Roche took over global development. That phase 1 trial (NCT06384352), sponsored by MediLink with Hoffmann-La Roche as collaborator, started in May 2024 in advanced solid tumours and includes parts combining YL211 with pembrolizumab in non-squamous non-small cell lung cancer. The payload chemistry is not stated in the sources read. No results are recorded here.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"MediLink and Roche licence announcement, 2 January 2024 (1stOncology copy)","url":"https://1stoncology.com/blog/?p=92748"},{"label":"ClinicalTrials.gov: YL211 phase 1 (NCT06384352)","url":"https://clinicaltrials.gov/study/NCT06384352"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["adc"],"targets":["met"],"drugs":[],"companies":["medilink","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06384352"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"modality":"Antibody-drug conjugate (c-MET)","mechanism":"An antibody that recognises c-MET, a growth-signal receptor on some cancer cells, carries a drug payload into those cells using MediLink's TMALIN conjugate technology. The payload is not named in the sources read.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/yl211/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct06384352","kind":"trial","name":"Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","route":"/trials/nct06384352/"}]}}